NLRP3 and COVID-19: Thus, the NLRP3 inflammasome may be a potential target for the treatment of COVID-19 [191,194], which is strongly supported by studies showing improved saturation, reduced hospitalization time and reduced mortality in patients with COVID-19 after treatment with NLRP3 inflammasome inhibitors such as Tranilast [200] or colchicine [198].